{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:26:00Z","timestamp":1790853960107,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.vaccine.2009.07.076","type":"journal-article","created":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T07:06:52Z","timestamp":1249974412000},"page":"6504-6511","source":"Crossref","is-referenced-by-count":61,"title":["A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra\u2122): Immunogenicity and safety profile"],"prefix":"10.1016","volume":"27","author":[{"given":"Hanna","family":"Czajka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Zepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Douha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.07.076_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e3180616c8f","article-title":"Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib2","unstructured":"Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996;45:1\u201336."},{"key":"10.1016\/j.vaccine.2009.07.076_bib3","first-page":"272","article-title":"Varicella-related deaths\u2014United States, January 2003\u2013June 2004","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2009.07.076_bib4","series-title":"Epidemiology and prevention of vaccine-preventable diseases","first-page":"175","article-title":"Varicella","author":"Centers for Disease Control and Prevention","year":"2007"},{"key":"10.1016\/j.vaccine.2009.07.076_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1542\/peds.2004-0012","article-title":"Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States","volume":"114","author":"Davis","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2009.07.076_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa042271","article-title":"Decline in mortality due to varicella after implementation of varicella vaccination in the United States","volume":"352","author":"Nguyen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2009.07.076_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2009.07.076_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.07.076_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib10","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.07.076_bib11","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1086\/522163","article-title":"Varicella vaccination in Japan, South Korea, and Europe","volume":"197","author":"Sadzot-Delvaux","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.076_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00431-007-0424-0","article-title":"Varicella vaccination in Europe: are we ready for a universal childhood programme?","volume":"167","author":"Sengupta","year":"2008","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2009.07.076_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2009.07.076_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0264-410X(02)00459-0","article-title":"Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine","volume":"21","author":"Nolan","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib16","series-title":"25th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Antibody persistence and varicella breakthrough case assessment two years after administration of measles-mumps-rubella-varicella (MMRV) vaccine in children aged 11-23 months","author":"Zepp","year":"2007"},{"key":"10.1016\/j.vaccine.2009.07.076_bib17","series-title":"International congress of pediatrics","article-title":"Varicella vaccination in healthy children: assessment of one versus two doses in two age strata (15 mths-2 yrs and 2-6 yrs old)","author":"Arsene","year":"2007"},{"key":"10.1016\/j.vaccine.2009.07.076_bib18","series-title":"International congress of pediatrics","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella vaccine in children from two age strata (15 mths-2 yrs and 2-6 yrs old) primed with measles-mumps-rubella vaccine","author":"Arsene","year":"2007"},{"key":"10.1016\/j.vaccine.2009.07.076_bib19","unstructured":"GlaxoSmithKline. GlaxoSmithKline clinical trial register: 104020 (MeMuRu-OKA-043). Available from: http:\/\/www.gsk-clinicalstudyregister.com\/ [accessed 2 October, 2007]."},{"key":"10.1016\/j.vaccine.2009.07.076_bib20","series-title":"24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Assessment of varicella breakthrough cases one year after administration of two doses of a measles, mumps, rubella, varicella vaccine in the second year of life","author":"Habermehl","year":"2006"},{"key":"10.1016\/j.vaccine.2009.07.076_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles\u2013mumps\u2013rubella\u2013varicella vaccine given as a second dose in children up to six years of age","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.inf.0000195626.35239.58","article-title":"Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children","volume":"25","author":"Knuf","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib23","series-title":"24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Persistence of functional antibodies against mumps remains high one year after administration of two doses of a measles mumps, rubella, varicella (MMRV) vaccine in the second year of life","author":"Zepp","year":"2006"},{"key":"10.1016\/j.vaccine.2009.07.076_bib24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib25","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1128\/JCM.43.9.4847-4851.2005","article-title":"Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays","volume":"43","author":"Mauldin","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2009.07.076_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1017\/S0950268807008266","article-title":"Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia","volume":"135","author":"Tischer","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2009.07.076_bib27","series-title":"24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Use of a neutralisation assay as an alternative for assessing mumps immunisation status","author":"Dodet","year":"2006"},{"key":"10.1016\/j.vaccine.2009.07.076_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.vaccine.2009.07.076_bib29","series-title":"26th annual meeting of the European Society for Pediatric Infectious Diseases (ESPID)","article-title":"Antibody persistence and varicella breakthrough case assessment three years after administration of measles-mumps-rubella-varicella (MMRV) vaccine in children aged 11-23 months","author":"Zepp","year":"2008"},{"key":"10.1016\/j.vaccine.2009.07.076_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/jinf.2001.0930","article-title":"MMR vaccine: review of benefits and risks","volume":"44","author":"Miller","year":"2002","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2009.07.076_bib31","first-page":"E0503243","article-title":"Decline in measles in WHO European Region but rubella remains high","volume":"10","author":"Muscat","year":"2005","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2009.07.076_bib32","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1001\/jama.284.20.2643","article-title":"Mumps and rubella eliminated from Finland","volume":"284","author":"Peltola","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2009.07.076_bib33","first-page":"418","article-title":"Global status of mumps immunization and surveillance","volume":"80","author":"World Health Organization","year":"2005","journal-title":"Wkly Epidemiol Rec"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.07.076_bib34","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1086\/522126","article-title":"Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine","volume":"197","author":"Shinefield","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.076_bib35","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2007.08.017","article-title":"Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis","volume":"25","author":"Hammerschmidt","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4161\/hv.1.6.2377","article-title":"Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children","volume":"1","author":"Halperin","year":"2005","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib37","unstructured":"Robert Koch Institut. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: Juli 2006. Epidemiol Bull 2006;30:235\u201354."},{"key":"10.1016\/j.vaccine.2009.07.076_bib38","first-page":"1212","article-title":"Notice to readers: licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2009.07.076_bib39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa064040","article-title":"Loss of vaccine-induced immunity to varicella over time","volume":"356","author":"Chaves","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2009.07.076_bib40","series-title":"Proceedings of the 44th annual meeting of the Infectious Diseases Society of America","article-title":"Primary immune failure after 1 dose of varicella vaccine may be the main cause of breakthrough infections in healthy vaccinated children","author":"Michalik","year":"2006"},{"key":"10.1016\/j.vaccine.2009.07.076_bib41","first-page":"258","article-title":"Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine","volume":"57","author":"ACIP","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2009.07.076_bib42","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0264-410X(00)00081-5","article-title":"Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines","volume":"18","author":"Crovari","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archpedi.158.4.323","article-title":"Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants","volume":"158","author":"Ipp","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2009.07.076_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF02962367","article-title":"Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children","volume":"26","author":"Usonis","year":"1998","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2009.07.076_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00006454-199901000-00011","article-title":"Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children","volume":"18","author":"Usonis","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib46","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2165\/00003495-200363190-00012","article-title":"Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2009.07.076_bib47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14760584.4.5.629","article-title":"Review of the Varilrix varicella vaccine","volume":"4","author":"Chiu","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.07.076_bib48","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1093\/infdis\/174.Supplement_3.S324","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine (Oka\/SB Bio) in healthy children","volume":"174","author":"Meurice","year":"1996","journal-title":"J Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.07.076_bib49","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1093\/infdis\/174.Supplement_3.S330","article-title":"Efficacy of high-titer live attenuated varicella vaccine in healthy young children","volume":"174","author":"Varis","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.076_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/0063030-200822060-00005","article-title":"Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix)","volume":"22","author":"Kreth","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2009.07.076_bib51","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/01.inf.0000232631.06763.8b","article-title":"Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain","volume":"25","author":"Arnedo-Pena","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(98)00260-6","article-title":"Varicella vaccination of health-care workers","volume":"17","author":"Burgess","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1155\/2000\/647245","article-title":"Reactogenicity to a live attenuated varicella vaccine in Canadian children","volume":"11","author":"Diaz-Mitoma","year":"2000","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.076_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.inf.0000114906.78716.64","article-title":"Use of a computerized database to study the effectiveness of an attenuated varicella vaccine","volume":"23","author":"Passwell","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib55","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1155\/2002\/907087","article-title":"Three-year follow-up of protection rates in children given varicella vaccine","volume":"13","author":"Scheifele","year":"2002","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.07.076_bib56","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000160947.89942.30","article-title":"Effectiveness of the Oka\/GSK attenuated varicella vaccine for the prevention of chickenpox in clinical practice in Israel","volume":"24","author":"Sheffer","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib57","series-title":"2nd World Congress of Pediatric Infectious Diseases","article-title":"Immunogenicity and reactogenicity of one or two doses of varicella in healthy non-immune adolescents and adults","author":"Wasi","year":"1999"},{"key":"10.1016\/j.vaccine.2009.07.076_bib58","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/adc.2007.126243","article-title":"Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005","volume":"93","author":"Quian","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2009.07.076_bib59","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0264-410X(91)90223-S","article-title":"Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients","volume":"9","author":"Brown","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.07.076_bib60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0140-6736(93)91069-X","article-title":"Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children","volume":"341","author":"Miller","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.07.076_bib61","first-page":"302","article-title":"Aseptic meningitis after vaccination against measles and mumps","volume":"8","author":"Cizman","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.07.076_bib62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/0140-6736(93)90684-9","article-title":"Aseptic meningitis after measles, mumps, and rubella vaccine","volume":"341","author":"Tesovic","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.07.076_bib63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/aje\/kwk045","article-title":"Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom","volume":"165","author":"Miller","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2009.07.076_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s15010-002-3027-8","article-title":"Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany","volume":"30","author":"Schlipkoter","year":"2002","journal-title":"Infection"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09011086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T21:29:47Z","timestamp":1545082187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09011086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":64,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0264410X09011086"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.07.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}